Venetoclax Plus Rituximab May Prolong Progression-free Survival in CLL

Share this content:
Researchers randomly assigned 389 patients with R/R CLL who were previously treated with at least 1 but not more than 3 lines of therapy to receive rituximab with venetoclax or bendamustine.
Researchers randomly assigned 389 patients with R/R CLL who were previously treated with at least 1 but not more than 3 lines of therapy to receive rituximab with venetoclax or bendamustine.

Venetoclax plus rituximab may prolong progression-free survival (PFS) compared with bendamustine plus rituximab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), according to results from a phase 3 study.1

In the MURANO study (ClinicalTrials.gov Identifier: NCT02005471), researchers randomly assigned 389 patients with R/R CLL who were previously treated with at least 1 but not more than 3 lines of therapy to receive rituximab with venetoclax or bendamustine.

The primary endpoint of the study was investigator-assessed PFS, and secondary endpoints included Independent Review Committee (IRC)-assessed PFS, PFS in patients with 17p deletion, overall survival, event-free survival, best overall response (defined as complete response [CR], complete response with incomplete marrow recovery [CRi], nodular partial remission [nPR], or PR), duration of response, time to next anti-CLL treatment, and percentage of patients achieving minimal residual disease negativity.

AbbVie, the co-developer of venetoclax, announced that study's primary endpoint was met. Full results and data from the MURANO study will be presented at an upcoming conference.

Venetoclax was previously granted accelerated approval by the US Food and Drug Administration for the treatment of patients with the 17p deletion CLL, and also received Breakthrough Therapy Designation for the treatment of patients with R/R CLL in combination with rituximab.

Reference

  1. AbbVie announces positive topline results from phase 3 trial evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) tablets in combination with Rituxan® (rituximab) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia [news release]. North Chicago, IL: AbbVie; September 18, 2017. https://news.abbvie.com/news/abbvie-announces-positive-topline-results-from-phase-3-trial-evaluating-venclextavenclyxto -venetoclax-tablets-in-combination-with-rituxan-rituximab-for-treatment-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia.htm. Accessed September 18, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters